Amgen Boosts U.S. Manufacturing with $300M Puerto Rico Expansion

Event summary

  • Amgen announces $300M investment in its Puerto Rico biologics manufacturing facility, part of a $2B U.S. expansion over the past year.
  • Total investments in Puerto Rico now approach $1B, including $650M previously announced.
  • Expansion strengthens domestic supply chain resilience and supports hundreds of construction jobs.
  • Investments enabled by pro-growth tax policies from TCJA and One Big Beautiful Bill Act of 2025.

The big picture

Amgen's latest investment underscores a broader industry trend of reshoring biopharmaceutical manufacturing to enhance supply chain security. The $2B in U.S. investments over the past year reflect strategic responses to geopolitical risks and regulatory incentives. This expansion positions Amgen to strengthen its domestic production footprint while leveraging Puerto Rico's established biomanufacturing ecosystem.

What we're watching

Supply Chain Resilience
How Amgen's increased U.S. manufacturing capacity will affect its supply chain vulnerability during global disruptions.
Regulatory Dynamics
Whether Puerto Rico's pro-business policies can sustain long-term biopharmaceutical investment.
Execution Risk
The pace at which Amgen can integrate and operationalize these manufacturing expansions.